<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535976</url>
  </required_header>
  <id_info>
    <org_study_id>STU00048723</org_study_id>
    <nct_id>NCT01535976</nct_id>
  </id_info>
  <brief_title>Ketamine Infusion and Hypoventilation</brief_title>
  <official_title>The Effect of Ketamine in The Prevention of Hypoventilation in Patients With and Without a Positive Berlin Questionnaire Undergoing Deep Sedation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Procedures performed under sedation have the same severity in regards to morbidity and
      mortality as procedures performed under general anesthesia1. The demand for anesthesia care
      outside the operating room has increased tremendously and it poses, according to a closed
      claim analysis, major risks to patients . Both closed claim analysis identified respiratory
      depression due to oversedation as the main risk to patients undergoing procedures under
      sedation. The major problem is that hypoventilation is only detected at very late stages in
      patients receiving supplemental oxygen. Besides the respiratory effects of hypoventilation,
      hypercapnia can also lead to hypertension, tachycardia, cardiac arrhythmias and seizures.

      The incidence of anesthetized patients with obstructive sleep apnea has increased
      substantially over the last years along with the current national obesity epidemic. These
      patients are at increased risk of hypoventilation when exposed to anesthetic drugs. The
      context of the massive increase in procedural sedation and the extremely high prevalence of
      obstructive sleep apnea poses major respiratory risks to patients and it may, in a near
      future, increase malpractice claims to anesthesiologists. The development of safer anesthesia
      regimen for sedation are, therefore, needed. The establishment of safer anesthetics regimen
      for sedation is in direct relationship with the anesthesia patient safety foundation
      priorities. It addresses peri-anesthetic safety problems for healthy patient's. It can also
      be broadly applicable and easily implemented into daily clinical care.

      Ketamine has an established effect on analgesia but the effects of ketamine on ventilation
      have not been clearly defined. The lack of validated and sensitive instruments to evaluate
      the effects of ketamine on ventilation is an important reason for the conflicting results.The
      investigators have demonstrated that the transcutaneous carbon dioxide monitor is accurate in
      detecting hypoventilation in patients undergoing deep sedation. Animal data suggest that when
      added to propofol in a sedation regimen, ketamine decreased hypoventilation when compared to
      propofol alone. It is unknown if ketamine added to a commonly used sedative agent (propofol)
      can decrease the incidence and severity of hypoventilation in patients undergoing deep
      sedation. It is also unknown if the effect of ketamine on ventilation are different in
      patients with and without obstructive sleep apnea.

      The investigators hypothesized that patients receiving ketamine and propofol will develop
      less intraoperative hypoventilation than patients receiving propofol alone. The investigators
      also hypothesized that this effect will be even greater in patients with obstructive sleep
      apnea than patients without obstructive sleep apnea.

      Significance: Respiratory depression due to oversedation was identified twice as the major
      factor responsible for claims related to anesthesia. The high prevalence of obstructive sleep
      apnea combined with more complex procedures done in outpatient settings can increase physical
      risks to patients and liability cases to anesthesiologists. The main goal of this project is
      to establish the effect of ketamine in preventing respiratory depression to patients
      undergoing procedures under sedation. If the investigators confirm the their hypothesis ,
      their findings can be valuable not only to anesthesiologist but also to other specialties (
      Emergency medicine, gastroenterologists, cardiologists, radiologists) that frequently
      performed procedural sedation. The research questions is;does ketamine prevent
      hypoventilation during deep sedation? The hypotheses is; ketamine will prevent
      hypoventilation during sedation cases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative Hypoventilation</measure>
    <time_frame>8 hours</time_frame>
    <description>Subjects receiving intraoperative ketamine in addition to propofol will demonstrate less hypoventilation during the surgical procedure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Hypoventilation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>.9 normal saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of ketamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator: Placebo
.9 normal saline infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I,II

          -  Age 18-64

          -  Females undergoing surgical procedures requiring sedation

        Exclusion Criteria:

          -  Pregnant subjects

          -  Breastfeeding

          -  Patients or surgeon request

             ---Drop Out:

          -  Patient or surgeon request,

          -  Conversion to general anesthesia

          -  Inability to obtain data from Co2 monitor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gildasio De Oliveira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prentice Womens Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <results_first_submitted>November 11, 2013</results_first_submitted>
  <results_first_submitted_qc>February 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2014</results_first_posted>
  <last_update_submitted>February 18, 2014</last_update_submitted>
  <last_update_submitted_qc>February 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Gildasio De Oliveira</investigator_full_name>
    <investigator_title>Gildasio De Oliveira, M.D. Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoventilation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Hospital based recruitment. From August 2011 to June 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>Infusion of ketamine
Ketamine : Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>.9 normal saline infusion
Placebo : Placebo Comparator: Placebo
.9 normal saline infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>Infusion of ketamine
Ketamine : Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case along with propofol 100 mcg/kg/min</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>normal saline infusion
Placebo : Placebo Comparator: Placebo
normal saline infusion along with propofol 100 mcg/kg/min</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.4" spread="7.67"/>
                    <measurement group_id="B2" value="46.89" spread="7.35"/>
                    <measurement group_id="B3" value="47.65" spread="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraoperative Hypoventilation</title>
        <description>Subjects receiving intraoperative ketamine in addition to propofol will demonstrate less hypoventilation during the surgical procedure.</description>
        <time_frame>8 hours</time_frame>
        <population>The median percentage of the sedation time with TCO2 &gt; 50 mmHg</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Infusion of ketamine
Ketamine : Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case along with propofol 100 mcg/kg/min.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>normal saline infusion
Placebo : Placebo Comparator: Placebo
normal saline infusion along with propofol 100 mcg/kg/min</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Hypoventilation</title>
          <description>Subjects receiving intraoperative ketamine in addition to propofol will demonstrate less hypoventilation during the surgical procedure.</description>
          <population>The median percentage of the sedation time with TCO2 &gt; 50 mmHg</population>
          <units>% time</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="95" lower_limit="0" upper_limit="83"/>
                    <measurement group_id="O2" value="65" lower_limit="0" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>Infusion of ketamine
Ketamine : Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>.9 normal saline infusion
Placebo : Placebo Comparator: Placebo
.9 normal saline infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We did not use depth of anesthesia monitor guided protocol due to controversial effects of ketamine of the correlation of processed EEG monitor and clinical levels of sedation. We did not use opioids as part of the protocol.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gildasio De Oliveira MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-472-3573</phone>
      <email>g-jr@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

